GSK2190915 100mg

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 1

A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin

CompletedNCT01411111

GlaxoSmithKlineAsthma

Start: 2011-01-06End: 2011-02-23Updated: 2017-07-25

A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.

WithdrawnNCT01721135

GlaxoSmithKlineAsthma

Start: 2010-09-30End: 2014-12-31Updated: 2013-08-21

Phase 2

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

CompletedNCT01147744

GlaxoSmithKlineAsthma

Start: 2010-06-28End: 2011-10-06Updated: 2017-10-02

GSK2190915 Neutrophilic Asthma Study

CompletedNCT01471665

GlaxoSmithKlineAsthma

Start: 2011-06-30End: 2012-05-31Updated: 2016-11-22

Related Papers

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study.

2013-05-1723 citations